Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes
Abstract
The management of diabetes in women with gestational diabetes and in children and adolescents with type 1 diabetes presents challenges that require therapeutic options that address the unique needs of these patients. Technosphere® insulin (TI), the main component of the Afrezza® Inhalation System, has the potential to address these challenges by improving glycemic management, reducing hypoglycemia, and promoting treatment adherence. TI is characterized by a rapid onset of action and a short duration of effect, distinguishing it from traditional injectable rapid-acting insulin analogs. This article discusses greater flexibility in insulin delivery, along with potential applications, benefits, and challenges of treatment with Technosphere inhaled insulin in these two patient populations.
Fields of Study & Subjects
Inhalation and Respiratory Drug Delivery
Neonatal Respiratory Health Research
Advanced Drug Delivery Systems
Publication details
- Journal / source
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Volume
- 28
- Issue
- 1_suppl
- Pages
- 43S–54S
- Publication date
- 1 February 2026
- Language
- EN